OREGA BIOTECH

OREGA BIOTECH est membre de Lyonbiopôle

General information

Espace Europeen, Bat G, 15 chemin du Saquin

69130 Ecully

Incorporated in: 2010/03/09

Number of employees: 11


More information

 

Main activity

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. OREGA Biotech’s business strategy is to bring its R&D programs up to proof of concept and then enter into a partnership and license agreement with larger biotechs or pharmaceutical companies at early stage. The company is building on a strong IP strategy, high level scientific publications and relies on a strong academic and industrial network. The company is managed by Gilles Alberici, PhD, CEO and Jeremy Bastid, PhD, COO.


Funding

Private funding obtained: 1M€ (2010) and undisclosed amount (2014)

Public funding obtained: Approx. 3 000 k€

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Oncology


Activities
Therapeutics, Pharma or Biotech


Technologies
Antibodies - Protein - Peptide